<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02415439</url>
  </required_header>
  <id_info>
    <org_study_id>VBP15-001</org_study_id>
    <nct_id>NCT02415439</nct_id>
  </id_info>
  <brief_title>A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReveraGen BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReveraGen BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety, tolerability, and PK of various
      increasing single and multiple doses of VBP15 in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Effects After a Single Dose of VBP15</measure>
    <time_frame>Participants will be followed for the duration of hospital stay of 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay of 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP15</measure>
    <time_frame>Participants will be followed for the duration of hospital stay of 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Effects After 14 Daily Doses of VBP15</measure>
    <time_frame>Participants will be followed for the duration of hospital stay of 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) After 14 Daily Doses of VBP15 (0 Through 72 Hours Post Dose)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay of 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of VBP15 After 14 Daily Doses of VBP15</measure>
    <time_frame>Participants will be followed for the duration of hospital stay of 15 days</time_frame>
  </primary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>VBP15- 0.1 mg/kg SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBP15- 0.3 mg/kg SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBP15- 1.0 mg/kg SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBP15- 3.0 mg/kg SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBP15- 8.0 mg/kg Fasting SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBP15- 8.0 mg/kg Fed SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBP15- 20.0 mg/kg SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects were orally administered a placebo under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBP15- 1.0 mg/kg 14 Day MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBP15- 3.0 mg/kg 14 Day MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBP15- 9.0 mg/kg 14 Day MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBP15- 20.0 mg/kg 14 Day MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects were orally administered placebo for 14 days under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBP15</intervention_name>
    <arm_group_label>VBP15- 0.1 mg/kg SAD</arm_group_label>
    <arm_group_label>VBP15- 0.3 mg/kg SAD</arm_group_label>
    <arm_group_label>VBP15- 1.0 mg/kg SAD</arm_group_label>
    <arm_group_label>VBP15- 3.0 mg/kg SAD</arm_group_label>
    <arm_group_label>VBP15- 8.0 mg/kg Fasting SAD</arm_group_label>
    <arm_group_label>VBP15- 8.0 mg/kg Fed SAD</arm_group_label>
    <arm_group_label>VBP15- 20.0 mg/kg SAD</arm_group_label>
    <arm_group_label>VBP15- 1.0 mg/kg 14 Day MAD</arm_group_label>
    <arm_group_label>VBP15- 3.0 mg/kg 14 Day MAD</arm_group_label>
    <arm_group_label>VBP15- 9.0 mg/kg 14 Day MAD</arm_group_label>
    <arm_group_label>VBP15- 20.0 mg/kg 14 Day MAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo - SAD</arm_group_label>
    <arm_group_label>Placebo MAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For the Single Ascending Dose Study (SAD): Male subjects, ages 18 to 65 years,
             inclusive.

          -  For the Multiple Ascending Dose Study (MAD): Male subjects or female subjects of
             nonchildbearing potential ages 18 to 65, inclusive.

        Exclusion Criteria:

          -  For the MAD Study: Women of childbearing potential.

          -  Clinically significant abnormal laboratory parameters
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <results_first_submitted>June 9, 2016</results_first_submitted>
  <results_first_submitted_qc>November 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2017</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>adult</keyword>
  <keyword>volunteers</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In the single ascending dose (SAD) study, subjects were assigned to 1 of 7 dose groups and received a single oral dose of VBP15 or placebo. The multiple ascending dose (MAD) was initiated after a review of safety data from SAD groups. In the MAD study, subjects were randomized to 1 of 4 groups to receive VBP15 or placebo once daily for 14 days</recruitment_details>
      <pre_assignment_details>An escalating-dose design was chosen for the SAD and MAD studies to allow increase of the dose after assessment of safety and tolerability of each preceding dose. Escalation to the next higher dose was performed using a factor of 3 for each subsequent dose until a maximum of 20 mg/kg was reached. No subject received more than 1 dose level of VBP15.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VBP15- 0.1 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="P2">
          <title>VBP15- 0.3 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="P3">
          <title>VBP15- 1.0 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="P4">
          <title>VBP15- 3.0 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="P5">
          <title>VBP15- 8.0 mg/kg Fasted SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="P6">
          <title>VBP15- 8.0 mg/kg Fed SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high calorie meal.</description>
        </group>
        <group group_id="P7">
          <title>VBP15- 20.0 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="P8">
          <title>Placebo SAD</title>
          <description>Subjects were orally administered a single dose of placebo under fasted conditions.</description>
        </group>
        <group group_id="P9">
          <title>VBP15- 1.0 mg/kg 14 Day MAD</title>
          <description>Subjects were orally administered VBP15 at 1.0 mg/kg daily for 14 days under fasted conditions.</description>
        </group>
        <group group_id="P10">
          <title>VBP15- 3.0 mg/kg 14 Day MAD</title>
          <description>Subjects were orally administered VBP15 at 3.0 mg/kg daily for 14 days under fasted conditions.</description>
        </group>
        <group group_id="P11">
          <title>VBP15- 9.0 mg/kg 14 Day MAD</title>
          <description>Subjects were orally administered VBP15 at 9.0 mg/kg daily for 14 days under fasted conditions.</description>
        </group>
        <group group_id="P12">
          <title>VBP15- 20 mg/kg 14 Day MAD</title>
          <description>Subjects were orally administered VBP15 at 20.0 mg/kg daily for 14 days under fasted conditions.</description>
        </group>
        <group group_id="P13">
          <title>Placebo MAD</title>
          <description>Subjects were orally administered placebo daily for 14 days under fasted conditions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VBP15- 0.1 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions</description>
        </group>
        <group group_id="B2">
          <title>VBP15- 0.3 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions</description>
        </group>
        <group group_id="B3">
          <title>VBP15- 1.0 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions</description>
        </group>
        <group group_id="B4">
          <title>VBP15- 3.0 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions</description>
        </group>
        <group group_id="B5">
          <title>VBP15- 8.0 mg/kg Fasted SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions</description>
        </group>
        <group group_id="B6">
          <title>VBP15- 8.0 mg/kg Fed SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high calorie meal</description>
        </group>
        <group group_id="B7">
          <title>VBP15- 20.0 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions</description>
        </group>
        <group group_id="B8">
          <title>Placebo SAD</title>
          <description>Subjects were orally administered a single dose of placebo under fasted conditions</description>
        </group>
        <group group_id="B9">
          <title>VBP15- 1.0 mg/kg 14 Days MAD</title>
          <description>Subjects were orally administered VBP15 at 1.0 mg/kg daily for 14 days under fasted conditions</description>
        </group>
        <group group_id="B10">
          <title>VBP15 - 3.0 mg/kg 14 Days MAD</title>
          <description>Subjects were orally administered VBP15 at 3.0 mg/kg daily for 14 days under fasted conditions</description>
        </group>
        <group group_id="B11">
          <title>VBP15- 9.0 mg/kg 14 Days MAD</title>
          <description>Subjects were orally administered VBP15 at 9.0 mg/kg daily for 14 days under fasted conditions</description>
        </group>
        <group group_id="B12">
          <title>VBP15- 20.0 mg/kg 14 Days MAD</title>
          <description>Subjects were orally administered VBP15 at 20.0 mg/kg daily for 14 days under fasted conditions</description>
        </group>
        <group group_id="B13">
          <title>Placebo MAD</title>
          <description>Subjects were orally administered placebo daily for 14 days under fasted conditions</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="12"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="8"/>
            <count group_id="B14" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Effects After a Single Dose of VBP15</title>
        <time_frame>Participants will be followed for the duration of hospital stay of 4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VBP15- 0.1 mg/kg SAD</title>
            <description>Subjects were administered single dose of VBP15 at 0.1 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>VBP15- 0.3 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>VBP15- 1.0 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>VBP15- 3.0 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>VBP15- 8.0 mg/kg Fasting SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>VBP15- 8.0 mg/kg Fed SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high-fat/high calorie meal.</description>
          </group>
          <group group_id="O7">
            <title>VBP15- 20.0 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Placebo SAD</title>
            <description>Subjects were administered a single dose of placebo under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Effects After a Single Dose of VBP15</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose)</title>
        <time_frame>Participants will be followed for the duration of hospital stay of 4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VBP15- 0.1 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>VBP15- 0.3 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>VBP15- 1.0 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>VBP15- 3.0 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>VBP15- 8.0 mg/kg Fasted SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>VBP15- 8.0 mg/kg Fed SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high-fat/high calorie meal.</description>
          </group>
          <group group_id="O7">
            <title>VBP15- 20.0 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Placebo SAD</title>
            <description>Subjects were administered a single dose of placebo under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose)</title>
          <units>(hr*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="17"/>
                    <measurement group_id="O2" value="161" spread="16"/>
                    <measurement group_id="O3" value="486" spread="20"/>
                    <measurement group_id="O4" value="1578" spread="21"/>
                    <measurement group_id="O5" value="3997" spread="55"/>
                    <measurement group_id="O6" value="10139" spread="25"/>
                    <measurement group_id="O7" value="8545" spread="30"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP15</title>
        <time_frame>Participants will be followed for the duration of hospital stay of 4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VBP15- 0.1 mg/kg SAD</title>
            <description>Subjects were administered single dose of VBP15 at 0.1 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>VBP15- 0.3 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>VBP15- 1.0 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>VBP15- 3.0 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>VBP15- 8.0 mg/kg Fasting SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>VBP15- 8.0 mg/kg Fed SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high-fat/high calorie meal.</description>
          </group>
          <group group_id="O7">
            <title>VBP15- 20.0 mg/kg SAD</title>
            <description>Subjects were administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Placebo SAD</title>
            <description>Subjects were administered a single dose of placebo under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP15</title>
          <units>(ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="13"/>
                    <measurement group_id="O2" value="51" spread="17"/>
                    <measurement group_id="O3" value="122" spread="33"/>
                    <measurement group_id="O4" value="305" spread="24"/>
                    <measurement group_id="O5" value="718" spread="43"/>
                    <measurement group_id="O6" value="1817" spread="31"/>
                    <measurement group_id="O7" value="1648" spread="17"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Effects After 14 Daily Doses of VBP15</title>
        <time_frame>Participants will be followed for the duration of hospital stay of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VBP15- 1.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 1.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>VBP15- 3.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 3.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>VBP15- 9.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 9.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>VBP15- 20.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 20.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Placebo MAD</title>
            <description>Subjects were orally admistered placebo daily for 14 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Effects After 14 Daily Doses of VBP15</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) After 14 Daily Doses of VBP15 (0 Through 72 Hours Post Dose)</title>
        <time_frame>Participants will be followed for the duration of hospital stay of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VBP15- 1.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 1.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>VBP15- 3.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 3.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>VBP15- 9.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 9.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>VBP15- 20.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 20.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Placebo MAD</title>
            <description>Subjects were orally admistered placebo daily for 14 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) After 14 Daily Doses of VBP15 (0 Through 72 Hours Post Dose)</title>
          <units>(hr*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="794" spread="22"/>
                    <measurement group_id="O2" value="1494" spread="19"/>
                    <measurement group_id="O3" value="4366" spread="20"/>
                    <measurement group_id="O4" value="9309" spread="39"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration (Cmax) of VBP15 After 14 Daily Doses of VBP15</title>
        <time_frame>Participants will be followed for the duration of hospital stay of 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VBP15- 1.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 1.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>VBP15- 3.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 3.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>VBP15- 9.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 9.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>VBP15- 20.0 mg/kg 14 Days MAD</title>
            <description>Subjects were orally administered VBP15 at 20.0 mg/kg daily for 14 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Placebo MAD</title>
            <description>Subjects were orally admistered placebo daily for 14 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of VBP15 After 14 Daily Doses of VBP15</title>
          <units>(ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153" spread="16"/>
                    <measurement group_id="O2" value="281" spread="37"/>
                    <measurement group_id="O3" value="1082" spread="23"/>
                    <measurement group_id="O4" value="2416" spread="51"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VBP15- 0.1 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="E2">
          <title>VBP15- 0.3 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="E3">
          <title>VBP15- 1.0 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="E4">
          <title>VBP15- 3.0 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="E5">
          <title>VBP15- 8.0 mg/kg Fasted SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="E6">
          <title>VBP15- 8.0 mg/kg Fed SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high-fat/high calorie meal.</description>
        </group>
        <group group_id="E7">
          <title>VBP15- 20.0 mg/kg SAD</title>
          <description>Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.</description>
        </group>
        <group group_id="E8">
          <title>Placebo SAD</title>
          <description>Subjects were orally administered a single dose of placebo under fasted conditions.</description>
        </group>
        <group group_id="E9">
          <title>VBP15- 1.0 mg/kg 14 Days MAD</title>
          <description>Subjects were orally administered a dose of VBP15 at 1.0 mg/kg daily for 14 days under fasted conditions.</description>
        </group>
        <group group_id="E10">
          <title>VBP15- 3.0 mg/kg 14 Days MAD</title>
          <description>Subjects were orally administered a dose of VBP15 at 3.0 mg/kg daily for 14 days under fasted conditions.</description>
        </group>
        <group group_id="E11">
          <title>VBP15- 9.0 mg/kg 14 Days MAD</title>
          <description>Subjects were orally administered a dose of VBP15 at 9.0 mg/kg daily for 14 days under fasted conditions.</description>
        </group>
        <group group_id="E12">
          <title>VBP15- 20.0 mg/kg 14 Days MAD</title>
          <description>Subjects were orally administered a dose of VBP15 at 20.0 mg/kg daily for 14 days under fasted conditions.</description>
        </group>
        <group group_id="E13">
          <title>Placebo MAD</title>
          <description>Subjects were orally administered a dose of placebo daily for 14 days under fasted conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain, Left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Worsening of toothache-right upper molar</sub_title>
                <description>Toothache</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin, increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Elevated liver enzyme: ALT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain extremity left elbow</sub_title>
                <description>Arthralgia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric P. Hoffman, PhD</name_or_title>
      <organization>ReveraGen BioPharma, Inc.</organization>
      <phone>301-962-1578</phone>
      <email>eric.hoffman@reveragen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

